Global HER-2 Positive Breast Cancer Market to Grow at a CAGR of 9.90% over the Period 2015 - 2019; Finds New Report

Market Research Reports, Inc. has announced the addition of “Global HER-2 Positive Breast Cancer Market 2015 - 2019” research report to their website


Lewes, DE -- (SBWire) -- 03/11/2015 --Report forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

According to the lead analyst of this report, increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages.

According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen.

Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients.

Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

This report covers the following companies as the key players in the Global HER-2 Positive Breast Cancer Market: Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Sanofi SA.

Other Prominent Vendors in the market are: Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm, Eisai, Galena Biopharma, Halozyme Therapeutics, Hospira, Mylan, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Sun Pharmaceutical Industries, Synta Pharmaceuticals and Teva Pharmaceutical.

Key Regions
- Americas

Market Driver
- Increase in Population of Breast Cancer Patients
- For a full, detailed list, view our report

Market Challenge
- Poor Diagnosis and Screening
- For a full, detailed list, view our report

Market Trend
- Increase in Awareness
- For a full, detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 123 pages, "Global HER-2 Positive Breast Cancer Market 2015 - 2019" report covers the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Disease Overview, Pipeline Analysis, Market Landscap, Market Segmentation by Type of Therapy, Market Segmentation by Molecule Type, Market Segmentation by Route of Administration, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit-

Find all Diagnostics Reports at:

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at:

Media Relations Contact

Amitava Sen
VP - Sales & Marketing
Market Research Reports, Inc.

View this press release online at: